LUMOSA THERAPEUTICS CO LTD AI Stock Analysis
LUMOSA THERAPEUTICS CO LTD (6535) AI Stock Analysis
LUMOSA THERAPEUTICS CO LTD
(TPEx:6535)
The score is driven primarily by weak financial performance: minimal and shrinking revenue against large losses and an accelerating cash burn of roughly NT$356 million per year, with no path to self-funding. The main mitigating factor is a nearly debt-free balance sheet with about NT$1.51 billion of equity, which limits near-term solvency risk but is steadily eroding and raises the prospect of future dilution. Technicals reinforce the caution, with the share price below all key moving averages and negative MACD momentum. Valuation offers no support given negative earnings and no dividend, leaving the investment case dependent on clinical and partnering milestones rather than current results.
LUMOSA THERAPEUTICS CO LTD (6535) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 13.53B
- Dividend Yield
- ―
- Average Volume (3M)
- 278.67K
- Price to Earnings (P/E)
- -31.9
- Beta (1Y)
- 0.21
- Revenue Growth
- -24.84%
- EPS Growth
- 9.15%
- Country
- TW
- Employees
- 36
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
LUMOSA THERAPEUTICS CO LTD Business Overview & Revenue Model
Company Description
Lumosa Therapeutics Co., Ltd. is a clinical-stage pharmaceutical company, headquartered in Taiwan, focused on developing innovative therapies for neurological and oncological diseases. Its most advanced product, LT-1001, an injectable analgesic, has...
LUMOSA THERAPEUTICS CO LTD Financial Statement Overview
Summary
Lumosa is a pre-commercial biotech with negligible, declining revenue (about NT$36 million, down 8%) against a net loss of roughly NT$347 million and a net margin near -967%. Operating cash outflow widened to about NT$356 million, with free cash flow similarly negative and no self-funding capability. The offsetting strength is a near debt-free balance sheet, with debt-to-equity well under 1% and equity of about NT$1.51 billion funding 91% of assets. However, equity has eroded from NT$2.12 billion in 2021 and return on equity is around -23%, pointing to continued drawdown and possible dilution. Narrowing losses and improved gross margin (61% from 45%) are modest positives within a weak overall profile.
Income Statement
19Very NegativeBalance Sheet
71PositiveCash Flow
16Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 34.37M | 35.83M | 39.15M | 56.92M | 26.64M | 17.36M |
| Gross Profit | 18.25M | 21.87M | 17.71M | 41.48M | 14.56M | 9.89M |
| EBITDA | -254.62M | -322.23M | -428.24M | -226.68M | -482.13M | 128.31M |
| Net Income | -370.06M | -346.62M | -424.78M | -238.04M | -494.66M | 95.95M |
Balance Sheet | ||||||
| Total Assets | 1.37B | 1.65B | 2.13B | 1.66B | 1.89B | 2.35B |
| Cash, Cash Equivalents and Short-Term Investments | 633.00M | 798.34M | 1.35B | 844.31M | 1.18B | 1.45B |
| Total Debt | 3.48M | 6.92M | 8.48M | 12.61M | 4.69M | 11.49M |
| Total Liabilities | 123.58M | 131.04M | 205.46M | 227.69M | 215.72M | 230.11M |
| Stockholders Equity | 1.24B | 1.51B | 1.91B | 1.40B | 1.63B | 2.12B |
Cash Flow | ||||||
| Free Cash Flow | -257.63M | -357.07M | -296.78M | -343.23M | -302.74M | -453.18M |
| Operating Cash Flow | -257.63M | -356.41M | -296.33M | -328.21M | -300.46M | -452.60M |
| Investing Cash Flow | 249.88M | 366.10M | -787.10M | 240.58M | -69.20M | -36.98M |
| Financing Cash Flow | -6.85M | -63.59M | 893.62M | -3.94M | 46.17M | 431.28M |
LUMOSA THERAPEUTICS CO LTD Peers Comparison
Overall Rating
TW:657642Neutral
TW:661740Underperform
TW:694540Underperform- TW:653539Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:6576 | 42Neutral | TWD 11.52B | 524.28 | ― | ― | 6.41% | ― |
| TW:6617 | 40Underperform | TWD 15.11B | -89.26 | ― | ― | 11.66% | -72.43% |
| TW:6945 | 40Underperform | TWD 11.22B | -20.83 | ― | ― | ― | ― |
| TW:6535 | 39Underperform | TWD 12.33B | -31.94 | ― | ― | -24.84% | 9.15% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:6535 | LUMOSA THERAPEUTICS CO LTD | 73.50 | -116.50 | -61.32% | |
| TW:6467 | TAHO Pharmaceuticals Ltd | 246.00 | 70.00 | 39.77% | |
| TW:6576 | Foresee Pharmaceuticals Co., Ltd. | 73.10 | -4.40 | -5.68% | |
| TW:6617 | Gongwin Biopharm Holdings Co., Ltd. | 118.50 | 32.10 | 37.15% | |
| TW:6748 | ACRO Biomedical Co., Ltd. | 168.50 | 107.65 | 176.90% | |
| TW:6945 | AP Biosciences, Inc. | 115.00 | 1.00 | 0.88% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026